Natixis Advisors’s TG Therapeutics TGTX Stock Holding History

Natixis Advisors’s Portfolio TGTX Stock Details TGTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$3.85M	Buy	70,178 +5,826	+9%	+$238K	﹤0.01%	1001
2026 Q1	$2.14M	Buy	64,352 +19,858	+45%	+$592K	﹤0.01%	1098
2025 Q4	$1.33M	Buy	44,494 +2,047	+5%	+$66.9K	﹤0.01%	1181
2025 Q3	$1.53M	Sell	42,447 -1,461	-3%	-$48.1K	﹤0.01%	1181
2025 Q2	$1.58M	Buy	43,908 +3,361	+8%	+$125K	﹤0.01%	1161
2025 Q1	$1.6M	Buy	40,547 +12,065	+42%	+$406K	﹤0.01%	1146
2024 Q4	$857K	Buy	+28,482	New	+$817K	﹤0.01%	1351

Other funds holding TGTX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

SCM

Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return

CAM

Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return

Natixis Advisors's TGTX Position: Q2 2026 in Review

Natixis Advisors increased its TG Therapeutics (TGTX) stake by 9.1% in Q2 2026, buying an estimated $238K and bringing the position to 70,178 shares worth $3.85M. The position accounts for ﹤0.01% of the portfolio, ranked #1001.

Natixis Advisors first reported a position in TGTX in Q4 2024 and has held it in 7 quarters since. 427 funds tracked by Wall St. Rank hold TGTX as of Q2 2026.

Natixis Advisors held 70,178 shares of TG Therapeutics worth $3.85M as of Q2 2026.
Natixis Advisors bought 5,826 TG Therapeutics shares in Q2 2026, an estimated $238K.
TG Therapeutics made up ﹤0.01% of Natixis Advisors's portfolio in Q2 2026, its #1001 holding.
Natixis Advisors first reported a position in TG Therapeutics in Q4 2024 and has held it in 7 quarters since.
427 funds tracked by Wall St. Rank held TG Therapeutics as of Q2 2026.

Based on Natixis Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.